Drugs / 10-1074-LS
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05079451 | Jan 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT05612178 | Jul 2023 → Mar 2027 expected | — | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05245292 | Dec 2022 → Dec 2025 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT04250636 | Oct 2020 → Jan 2022 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Phase 1 | NCT03554408 | Jun 2018 → Feb 2021 | HIV infectious disease | Rockefeller University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT06205602 Comparator | Jan 2025 → Feb 2029 expected | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Recruiting | No outcome recorded |
| Phase 2 | NCT05300035 Comparator | Apr 2024 → Dec 2026 expected | HIV infectious disease | ANRS, Emerging Infectious Diseases | Recruiting | No outcome recorded |
| Phase 2 | NCT04319367 Comparator | May 2021 → Jul 2027 expected | HIV infectious disease | Imperial College London | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 10-1074-LS | “Participants will receive three intravenous infusions of 3BNC117-LS (dosed at 30 mg /kg) and 10-1074-LS (dosed at 10 mg/kg) at weeks 0, 20 and 40.” NCT05612178 ↗7“Participants were randomly assigned (1:1) to receive two LS-bNAbs (3BNC117-LS and 10-1074-LS) in arm A or saline placebo in arm B” PMID 42202839 ↗ May 2026 “10-1074-LS and 3BNC117-LS” NCT05300035 ↗ |
| Action | Inhibit | “can block HIV from attacking cells in the body and from spreading to other parts of the body” NCT06205602 ↗ |
| Modality | Monoclonal antibody | “Monoclonal antibody” NCT03554408 ↗ |
| Route | Subcutaneous | “Subcutaneous injection of 10-1074-LS” NCT03554408 ↗ |